A new study released by BioCrossroads provides a glimpse into the impact of a federally-funded program in Indiana that harnesses the assets of some of the state’s most prominent life sciences institutions. The report, conducted by Faegre BD Consulting, calls the Indiana Clinical and Translational Science Institute a "leading participant and preeminent site" among its peers that are supported by the National Institutes of Health. The Indiana CTSI is led by the Indiana University School of Medicine and partners with Purdue University and the University of Notre Dame.
The Indiana CTSI, which was established in 2008, is a statewide consortium that aims to "accelerate the translation of basic, applied and clinical research discoveries into best practices and solutions to our most pressing health problems."
The program was launched nationally in 2006 by the NIH and now involves 62 academic medical institutions.
BioCrossroads Chief Executive Officer David Johnson says "with close to 150 medical schools nationwide, the Indiana University School of Medicine is distinguished by having one of only 62 NIH-funded CTSA award winning sites. Because it is the only such NIH-award winner in the state, the Indiana CTSI has a unique opportunity to leverage our highly connected regional life sciences environment – both with other academic partners and industry — to exploit opportunities that are extremely difficult to achieve in other locations around the country."
BioCrossroads Project Director Chris Eckerle says the report shows the Indiana CTSI does more with less funding than many collaborations of its kind.